Is Ga-68 dotatate FDA-approved, and what does the research show?

What is Ga-68 dotatate?

Ga-68 dotatate is a radioactive diagnostic agent: a drug given so that a scanner can find disease, not to treat it ¹. The label writes its name as gallium Ga 68 dotatate, and a 2016 research paper writes it 68Ga-DOTATATE ², ¹. Doctors use it with positron emission tomography (PET), a scan that maps where a radioactive tracer collects in the body ¹.

The drug has two parts ¹. Dotatate is "a cyclic 8 amino acid peptide with a covalently bound chelator," which means a small ring of eight amino acids with a chemical cage attached ¹. Amino acids are the units proteins are built from, and the cage holds a metal. The metal is gallium-68, a radioactive form of gallium ¹.

The approved product, NETSPOT, is a kit of two vials ¹. Its label says, "Before radiolabeling with gallium-68, the contents of this kit are not radioactive" ¹. Radiolabeling is the step of attaching the radioactive metal, which trained staff draw from a separate generator ¹. The label says radioactive drugs "should be used by or under the control of physicians who are qualified by specific training and experience in the safe use and handling of radionuclides" ¹. Radionuclides are radioactive atoms.

Is Ga-68 dotatate FDA-approved?

Yes. FDA approved NETSPOT, a "kit for the preparation of gallium Ga 68 dotatate injection," on June 1, 2016, under NDA 208547, its new drug application ¹, ³. Drugs@FDA lists the product's marketing status as "Prescription" as of November 9, 2026, the data date of that record ³. It is a prescription drug used only for diagnosis ¹, ³.

The label gives one indication ¹. NETSPOT, "after radiolabeling with gallium-68, is a radioactive diagnostic agent indicated for use with positron emission tomography (PET) for localization of somatostatin receptor positive neuroendocrine tumors (NETs) in adult and pediatric patients" ¹. Localization means finding where in the body the tumors are ¹.

Neuroendocrine tumors are "usually slow-growing malignancies, mostly of the respiratory and digestive tracts," in the words of a 2016 study ². The same study put their incidence in the United States at 2.5 to 5 per 100,000 people ². Most of them carry large numbers of somatostatin receptors on the cell surface, docking sites for the hormone somatostatin ². "Somatostatin receptor positive" describes a tumor with those docking sites, and they are what the drug seeks out ¹.

The label names no disease that Ga-68 dotatate treats ¹. The Drugs@FDA record marks the application "Orphan" ³, a designation FDA gives to drugs for rare diseases. The 2016 study likewise calls the agent "a designated orphan drug" ².

See the FDA status of every peptide, updated weekly.

How does Ga-68 dotatate work?

Ga-68 dotatate works as a tracer: it attaches to a target on tumor cells and gives off a signal that a scanner can read ¹. The description comes from the label of an FDA-approved diagnostic drug ¹. The drug "binds to somatostatin receptors, with highest affinity for subtype 2 receptors (SSTR2)" ¹. It binds to cells that carry those receptors, "including malignant cells, which overexpress SSTR2," meaning cancer cells that make more of the receptor than usual ¹. The 2016 study describes it as a somatostatin analog, a lab-made relative of that hormone ².

The gallium-68 supplies the signal ¹. It emits positrons, the particles a PET scanner detects, and the label says the images "indicate the presence and density of somatostatin receptors in tissues" ¹. A stronger signal therefore marks tissue with more of the receptor ¹.

One limit follows from that design, and the label states it ¹. "Tumors that do not bear somatostatin receptors will not be visualized," it says ¹. Healthy organs that carry the receptor take up the tracer too ¹. The label lists the pituitary, thyroid, spleen, adrenals, kidneys, pancreas, prostate, liver and salivary glands ¹.

What does the research show?

Ga-68 dotatate is approved by FDA for one use, and the label says its efficacy "was established in three open label single center studies" ¹. Open label means everyone knew which agent was given. Single center means one hospital ran each study ¹. All three were imaging studies, and none tested the drug as a treatment ¹.

Study A evaluated 97 adults with known or suspected neuroendocrine tumors, 41 men and 56 women, with a mean age of 54 ¹. Two independent readers, blinded to clinical information, read the PET images ¹. Their reads were compared with CT or MRI, two standard kinds of body scan, and with an older nuclear scan, indium In 111 pentetreotide ¹. Both comparisons were available for 78 patients, and the PET result agreed with CT or MRI in 74 of them ¹.

Of 50 patients whose tumors CT or MRI had located, the PET scan was positive in 48 ¹. Those 48 included 13 patients whose pentetreotide scan had been negative ¹. The PET scan was negative in 26 of the 28 patients whose CT or MRI was negative ¹.

A study of the same size as Study A, at Vanderbilt University Medical Center, was published online on January 14, 2016 ². Studied in people, in one hospital's study of 97 patients enrolled consecutively between March 2011 and November 2013: 90 had a proven neuroendocrine tumor ². Of the 97, 78 had a pentetreotide scan that could be compared ².

In the 78 patients whose two scans were compared, sensitivity was 96 percent for Ga-68 dotatate and 72 percent for pentetreotide ². Sensitivity is the share of patients with disease that a scan catches. The 95 percent confidence intervals, the ranges the true figures plausibly lie in, were 86 to 100 and 58 to 84 ².

Specificity, the share of patients without disease that a scan correctly clears, was 93 percent for both scans ². Its confidence interval ran from 77 to 99 percent ². The paper measured these figures against a diagnosis based on CT or MRI scans, surgical tissue confirmation, or both ². Adding the Ga-68 dotatate scan to earlier imaging changed the care plan for 28 of those 78, 36 percent ².

The authors concluded that the scan "was equivalent or superior to" pentetreotide imaging "in all 78 patients" ². They named limits: the patients' earlier scans varied in type and quality, and results were judged per patient, not per tumor ². Their sensitivity and specificity figures, they wrote, "may not reflect the true accuracy of either test" ². One false-positive result was due to splenosis, spleen tissue growing outside the spleen, with inflammation ².

Studies B and C were published studies that checked the scan against a reference standard ¹. That standard was histopathology, the study of tissue under a microscope, or clinical follow-up of up to 5 months ¹.

Study B involved 104 patients suspected of a neuroendocrine tumor ¹. The suspicion came from symptoms, raised tumor markers or an indeterminate tumor ¹. Tumor markers are substances measured in lab tests that can point to a tumor, and an indeterminate tumor is a growth whose nature tests have not settled. The study was assessed retrospectively, meaning from scans and records already made, by readers who were not blinded to clinical information ¹.

In Study B the reference standard found a tumor site in 36 patients ¹. The scan was positive in 29 of them and falsely negative in 7 ¹. In the 68 patients with no tumor found, it was negative in 61 and falsely positive in 7 ¹.

Study C involved 63 patients evaluated for a tumor's return ¹. Two central readers, blinded to clinical information, read the images independently ¹. Of 29 patients in whom the reference standard found a tumor, reader 1 correctly located it in 23 and reader 2 in 22 ¹. Of 34 patients with no tumor found, reader 1 was correct in 29 and reader 2 in 32 ¹.

For children, the label says efficacy "is based on extrapolation from adult studies," on receptor-binding studies and on one published pediatric study ¹. It also says the clinical studies "did not include sufficient numbers of subjects aged 65 and over" to show whether they respond differently ¹. Neither the label nor the 2016 study reports any effect on weight ², ¹. Neither tested the drug for metabolism, muscle, aging or performance ², ¹.

What are the side effects?

The label says safety "was evaluated in three single center studies" and in a survey of the scientific literature ¹. It reports, "No serious adverse reactions were identified" ¹. After approval, reports on NETSPOT or other somatostatin receptor imaging agents named nausea, vomiting, and pain and a burning sensation at the injection site ¹. They also named hypersensitivity, or allergic-type, reactions, "predominantly rash, pruritus, less frequently angioedema or features of anaphylaxis" ¹. Pruritus is itching, angioedema is swelling beneath the skin, and anaphylaxis is a severe, body-wide allergic reaction ¹.

The label notes that such reports are voluntary, so their frequency cannot always be reliably estimated ¹. In the 2016 study of 97 patients, "No participant had a trial-related event requiring treatment" ². Minor events occurred in 3 patients: itching at the injection site, an unexplained drop in blood oxygen, and a fast heart rate without symptoms ². Each resolved on its own ². Some follow-up blood results were missing for 28 patients ².

The label's first warning is radiation ¹. "Gallium Ga 68 dotatate contributes to a patient's overall long-term cumulative radiation exposure," it says ¹. It continues, "Long-term cumulative radiation exposure is associated with an increased risk of cancer" ¹. For a 75-kilogram adult, the label estimates an effective dose of "about 3.15 mSv" from the administered activity it assumes ¹. Effective dose is one figure for the radiation dose to the whole body, and the millisievert (mSv) is its unit.

In the label's dose table, the effective dose for each megabecquerel (MBq) of injected radioactivity is 0.021 mSv for an adult and 0.35 mSv for a newborn ¹. The label also says to "Avoid close contact with infants and pregnant women during the first 12 hours after administration" ¹. For breastfeeding, the label advises a woman to "pump and discard breast milk for 12 hours" ¹. The label says there are no studies of the drug in pregnant women, and it warns that radioactive emissions "can cause fetal harm" ¹. Under contraindications, its entry is the single word "None" ¹.

Another warning concerns scans that mislead ¹. Uptake "can also be seen in a variety of other tumor types," in splenosis, in thyroid disease or subacute inflammation, and as a normal variant in part of the pancreas ¹. So the label says a finding "may need to be confirmed by histopathology or other assessments" ¹. A negative scan in a patient with no history of these tumors "does not rule out the presence of NETs" ¹.

Two kinds of medicine can interfere with the scan ¹. Non-radioactive somatostatin analogs "competitively bind to the same somatostatin receptors," so the label tells physicians to time the scan around them ¹. Octreotide (Sandostatin) is one such drug ⁴. Repeated high doses of glucocorticoids, a class of steroid drugs, "may result in false negative imaging" ¹.

In sport

WADA, the World Anti-Doping Agency, does not name Ga-68 dotatate on its 2026 Prohibited List ⁵. Section S2 of that list covers peptide hormones, growth factors, related substances and mimetics, and it names neither dotatate nor any somatostatin analog ⁵. No other section names them either ⁵.

Because the drug is injected into a vein, one method rule is relevant, M2.2 ⁵. The list prohibits "Intravenous infusions and/or injections of more than a total of 100 mL per 12-hour period except for those legitimately received in the course of hospital treatments, surgical procedures or clinical diagnostic investigations" ⁵.

Section S0 of the list reads: "Any pharmacological substance which is not addressed by any of the subsequent sections of the List and with no current approval by any governmental regulatory health authority for human therapeutic use ... is prohibited at all times" ⁵. FDA approved NETSPOT as "a radioactive diagnostic agent" for PET imaging ¹.

What JumpstartMD offers

JumpstartMD does not prescribe Ga-68 dotatate. Our peptide library covers it so you have the facts on its FDA status and the evidence, current as of November 10, 2026.

Ready to talk?

Book FREE Consultation

Share your details and a JumpstartMD team member will reach out shortly. Or call 408.478.3496 for your free, no-obligation consultation.

Share your details and a JumpstartMD team member will reach out when we open.

Disclaimer

Compounded medications are not FDA-approved, and FDA does not review their safety, effectiveness, or quality before they are marketed. A licensed clinician decides after an evaluation whether a peptide is appropriate for you, and not every patient will qualify.